Tepotinib vs standard care for MET-mutated lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a targeted pill called tepotinib against standard treatments for advanced lung cancer with a specific MET gene change. It is for people whose cancer has progressed after at least one prior therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer has a specific change called MET exon 14 skipping mutation, found through a biopsy or blood test.
- You must have had at least one prior cancer treatment (chemo or immunotherapy), but no more than two total prior treatments.
- You can be active or need some help with daily activities (ECOG status 0, 1, 2, or 3).
- You must have adequate kidney, liver, and blood cell counts as shown by routine lab tests.
- You have not been treated before with a drug that targets MET (like crizotinib).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving targeted therapy before and after surgery helps people with a specific type of lung cancer (non-small cell lung cancer with a BRAF or MET mutation). The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests combining a targeted drug (bozitinib) with chemotherapy after lung cancer surgery to see if it can help prevent the cancer from coming back. The study is for people with a specific MET gene change in their lung cancer.
This trial tests a targeted drug for advanced non-small cell lung cancer that has a specific genetic change called MET exon 14 skipping. It aims to see if the drug can shrink tumors or slow the cancer's growth, and may help people who have or haven't had prior treatment.
This trial tests a combination of two targeted drugs, lazertinib and tepotinib, for people with advanced EGFR-mutant non-small cell lung cancer whose tumors show MET overactivity (high MET levels or MET gene copies) and have grown despite prior treatment with lazertinib. It aims to see if adding tepotinib can overcome that resistance.
This trial tests a combination of two drugs, tepotinib and ivonescimab, for people with a certain type of advanced non-small cell lung cancer that has a change called MET exon 14 skipping. The treatment aims to shrink tumors or slow their growth.
This study tests a new targeted pill (vebreltinib) for people with advanced non-small cell lung cancer that has a specific gene change (MET exon 14 mutation). It is for people who have not had much or any prior treatment. The goal is to see if this medicine can shrink tumors and improve outcomes.
Hear when a new MET Exon 14 Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.